Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiny Adams

Nurse Practitioner, Psychiatric/Mental Health Albuquerque, NM Nurse Practitioner

NPI 1669403218 CMS profile 11091326

4701 Montgomery Boulevard Northeast, Albuquerque, NM 87109

Open in the dashboard

General payments

$5,503

286 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiny Adams of Albuquerque, NM is reported in the CMS Open Payments database as having received $5,503 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $887 43
2024 General $1,143 54
2023 General $1,301 57
2022 General $1,048 71
2021 General $1,124 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiny Adams
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Tiny Adams were reported at $887. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Tiny Adams Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,124 $166 $54–$482 $132
2022 $1,048 $195 $66–$559 $149
2023 $1,301 $233 $82–$673 $160
2024 $1,143 $236 $84–$688 $164
2025 $887 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $1,054 53 payments
  2. AbbVie, Inc. $1,038 61 payments
  3. ITI, Inc. $909 42 payments
  4. Neurocrine Biosciences, Inc. $549 29 payments
  5. Teva Pharmaceuticals USA, Inc. $422 19 payments
  6. Otsuka America Pharmaceutical, Inc. $259 13 payments
  7. Sunovion Pharmaceuticals Inc. $207 12 payments
  8. Janssen Pharmaceuticals, Inc $171 8 payments
  9. Axsome Therapeutics, Inc. $164 8 payments
  10. Vanda Pharmaceuticals Inc. $156 7 payments
  11. Other $573 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,344 283 payments
  2. Education $158 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $920 54 payments
  2. CAPLYTA $773 36 payments
  3. LYBALVI Cns $745 35 payments
  4. ARISTADA Cns $723 39 payments
  5. ARISTADA Cns $723 39 payments
  6. ARISTADA Cns $479 25 payments
  7. ARISTADA Cns $479 25 payments
  8. LYBALVI Cns $346 15 payments
  9. ARISTADA INITIO $324 19 payments
  10. INGREZZA $286 12 payments
  11. Other $2,935 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,178

Median for Nurse Practitioner: 389

Drug cost

$111,403

Median for Nurse Practitioner: $21,885

Branded share of claims

16.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 37 $57,518
Abilify Maintena Aripiprazole Brand 16 $38,743
Aripiprazole Generic 35 $2,823
Vilazodone Hcl Generic 16 $1,500
Trazodone Hcl Generic 149 $922
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 23 $792
Paliperidone Er Paliperidone Brand 11 $727
Quetiapine Fumarate Generic 73 $679
Clonazepam Generic 70 $645
Olanzapine Generic 39 $537

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $314
$314 37 —
CAPLYTA
  • ITI, Inc. $258
$258 — —
Auvelity
  • Axsome Therapeutics, Inc. $120
$120 — —
REXULTI
  • Lundbeck LLC $60
  • Otsuka America Pharmaceutical, Inc. $36
$96 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record